Scouted selects products independently. If you purchase something from our posts, we may earn a small commission. Unless you ...

The absolute risk for thyroid cancer is low among patients receiving glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy, but risk is elevated in the first year of treatment, according to a ...

With with GLP-1 drugs, gastrointestinal issues, such as nausea, vomiting, constipation, and gastroesophageal reflux disease, ...

With respect to risks, GLP-1RA use was significantly associated with an increased risk of gastrointestinal disorders, hypotension, syncope, arthritic disorders, drug-induced pancreatitis, and other ...

For people with diabetes, the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with a reduced risk for certain disorders and conditions.

Glp-1 Analogues Market OverviewThe Glp analogues market size is expected to be worth USD 606.3 billion by 2034.The target market was valued at USD 45.3 billion in 2024.The market is projected to grow ...

In this cohort study, most patients with overweight or obesity discontinued glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy within 1 year, but those without type 2 diabetes had higher ...

Sitagliptin (Januvia™) is a new oral agent approved by the US FDA ... the primary enzyme degrading the incretin hormones, allowing glucagon-like peptide-1 and glucose-dependent insulinotropic ...

Collaborating with academic researchers, Novo Nordisk pioneered translating glucagon-like peptide 1 (GLP-1) from incretin hormone to pharmacologically useful GLP-1 analogues for the treatment of ...

Another trial in patients with T2D and mean A1c of 7.6%, previously treated with diet alone or single oral agent ... at doses of 1 mg weekly and above. These glucose effects remained consistent ...